Home → Ketamine-Assisted Psychotherapy

Ketamine-Assisted Psychotherapy: Evidence, Protocol, and Clinical Guide

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University
March 29, 2026

What Is Ketamine-Assisted Psychotherapy?

Ketamine-assisted psychotherapy (KAP) is a treatment approach that combines the administration of sub-anesthetic ketamine with structured psychotherapy. The premise is straightforward: ketamine produces a window of enhanced neuroplasticity, and psychotherapy conducted during or shortly after this window may produce deeper and more durable therapeutic effects than either intervention alone.

Ketamine is an NMDA receptor antagonist that has been used as an anesthetic since 1970. Over the past two decades, research has demonstrated its rapid antidepressant effects at sub-anesthetic doses, often producing measurable symptom improvement within hours rather than the weeks required by conventional antidepressants.

KAP takes this a step further. Rather than administering ketamine as a standalone pharmacological intervention and hoping for the best, it embeds the ketamine experience within a therapeutic framework designed to maximize the treatment's psychological impact.

How KAP Differs from Standalone Ketamine Infusions

The distinction matters clinically:

Standalone infusion clinics have proliferated in recent years. Many provide excellent medical care, but the purely pharmacological approach often leaves patients cycling through repeated infusions without the therapeutic scaffolding that might produce lasting change. KAP attempts to address this limitation.

The Neuroplasticity Window: Why Timing Matters

The scientific rationale for KAP rests on ketamine's effects on brain plasticity. Within hours of a sub-anesthetic ketamine dose, several neurobiological changes occur:

• Increased BDNF (brain-derived neurotrophic factor) -- promotes growth of new synaptic connections
• Enhanced synaptogenesis -- rapid formation of new synapses, particularly in the prefrontal cortex
• mTOR pathway activation -- cellular signaling cascade associated with synaptic protein synthesis
• Glutamate surge -- increased glutamate release triggers downstream plasticity cascades

This period of enhanced neural flexibility -- typically lasting 24 to 72 hours after a ketamine dose -- represents a window during which the brain may be more receptive to new learning and the reorganization of maladaptive thought patterns. Integration psychotherapy sessions are intentionally scheduled within this window to leverage these neurobiological effects.

Think of it this way: ketamine loosens the rigid neural circuits that maintain depressive thinking. Psychotherapy during the plasticity window provides the new patterns to replace them.

My Early Research: Ketamine and ECT at Emory

My interest in ketamine's therapeutic potential began during my residency at Emory University School of Medicine. In 2014, I co-authored a case report published in Psychosomatics with Drs. Patricio Riva-Posse and Ann Schwartz, documenting a novel use of pre-ECT ketamine infusion in a patient with severe treatment-resistant depression.

The case involved a 52-year-old man with a 25-year history of depression who had failed multiple medication trials and had only a transient one-month response to a previous course of 12 ECT treatments. During his second admission for depression with catatonic features, we administered a single sub-anesthetic ketamine infusion (0.5 mg/kg over 40 minutes) before beginning ECT.

This work was conducted with the mentorship and intellectual framework provided by Dr. John Krystal at Yale, one of the pioneers of ketamine research in psychiatry. Our case illustrated the potential of subanesthetic ketamine as an augmentation strategy -- not as a replacement for established treatments, but as a facilitating agent that could enhance and accelerate the response to other interventions.

The limitations were clear: this was a single case report, and the patient received multiple simultaneous interventions (ketamine, ECT, and a tricyclic antidepressant). But the rapid, dramatic response in a patient with years of treatment resistance was clinically striking and consistent with the emerging literature on ketamine's antidepressant properties.

The Evidence Base for Ketamine in Depression

Since the landmark 2000 study by Berman and colleagues demonstrating ketamine's antidepressant effects, the evidence has grown substantially:

• Zarate et al. (2006) -- Randomized controlled trial showing a single ketamine infusion produced rapid antidepressant effects in treatment-resistant depression within 2 hours, with effects lasting up to 1 week
• Murrough et al. (2013) -- Two-site randomized controlled trial confirming ketamine's antidepressant efficacy, with a response rate of 64% vs. 28% for active placebo at 24 hours
• Zarate et al. (2012) -- Replication of ketamine's antidepressant effects in bipolar depression
• Diazgranados et al. (2010) -- Randomized add-on trial demonstrating efficacy in treatment-resistant bipolar depression

The FDA approved esketamine (Spravato), the S-enantiomer of ketamine, as a nasal spray for treatment-resistant depression in 2019 and for depressive symptoms with acute suicidal ideation in 2020. While esketamine and racemic ketamine have different pharmacological profiles, the approval validated the therapeutic principle underlying ketamine-based treatments.

Evidence Specifically for KAP

The evidence for the psychotherapy-assisted model is still developing. Several clinical trials and observational studies suggest that combining ketamine with psychotherapy produces better outcomes than ketamine alone, but the field needs larger randomized controlled trials. What we do have:

• Preliminary data showing KAP produces more sustained remission than repeated ketamine infusions alone
• Theoretical support from the neuroplasticity literature suggesting enhanced therapeutic learning during the post-ketamine window
• Parallels with MDMA-assisted psychotherapy for PTSD, where the combination approach has shown dramatic efficacy in Phase 3 trials
• Clinical consensus from practitioners that the therapeutic framework enhances and extends ketamine's benefits

Patient Selection: Who Is a Candidate for KAP?

Appropriate patient selection is critical for both safety and efficacy.

Strong Candidates

• Treatment-resistant depression (failed 2+ adequate antidepressant trials)
• Severe depression with acute suicidal ideation requiring rapid intervention
• Patients who are psychologically minded and motivated for therapeutic work
• Those with stable medical conditions and no cardiovascular contraindications
• Patients able to commit to the full treatment protocol including integration sessions

Contraindications

• Uncontrolled hypertension
• Active psychotic symptoms or history of psychotic disorders (schizophrenia, schizoaffective disorder)
• Active substance use disorders, particularly involving ketamine, PCP, or other dissociative drugs
• Unstable cardiovascular disease, aneurysm, or history of intracranial hemorrhage
• Pregnancy
• Conditions worsened by elevated intracranial or intraocular pressure (e.g., glaucoma)

Requires Careful Consideration

• History of mania (ketamine may trigger manic episodes in some bipolar patients)
• Borderline personality disorder (dissociative features may be destabilizing)
• Active benzodiazepine use (may attenuate ketamine's effects)
• Elderly patients or those with significant medical comorbidities

The KAP Treatment Protocol

A well-structured KAP protocol involves three distinct phases:

Phase 1: Preparation (1-2 Sessions)

Before any ketamine is administered, preparation sessions accomplish several goals:

• Comprehensive psychiatric evaluation and medical screening
• Establishing therapeutic goals and identifying target symptoms
• Psychoeducation about the ketamine experience, including what to expect (dissociative effects, altered perception, emotional intensification)
• Developing a therapeutic alliance and trust with the treatment team
• Setting intentions for the treatment course
• Addressing fears, expectations, and misconceptions

Phase 2: Ketamine Dosing Sessions (4-6 Sessions)

Each dosing session follows a structured format:

• Pre-session check-in: Review of current symptoms, intentions for the session, vital sign assessment
• Administration: Sub-anesthetic ketamine (typically 0.5 mg/kg IV over 40 minutes, or sublingual/intramuscular routes depending on the protocol)
• Guided experience: A trained therapist is present throughout, providing a safe container and gentle guidance without forcing the experience in any particular direction
• Medical monitoring: Continuous vital sign monitoring, with a physician available
• Recovery period: 1-2 hours of post-infusion observation
• Brief post-session processing: Initial reflections while the experience is fresh

Sessions are typically spaced 1-2 weeks apart to allow time for integration.

Phase 3: Integration (After Each Dosing Session)

Integration is where much of the therapeutic work happens:

• Processing insights, emotions, and imagery from the ketamine experience
• Connecting ketamine-facilitated insights to existing therapeutic goals
• Identifying and reinforcing new cognitive and emotional patterns
• Developing concrete behavioral changes based on session insights
• Monitoring symptom trajectory and adjusting the treatment plan

The integration sessions are scheduled within the 24-72 hour neuroplasticity window when possible, capitalizing on enhanced neural flexibility for therapeutic learning.

Safety Considerations

Ketamine has been used safely as an anesthetic for over 50 years. At the sub-anesthetic doses used in KAP, the safety profile is favorable, but not without risks that require competent medical management.

Common Side Effects During Sessions

Serious Risks

• Cardiovascular: Ketamine raises blood pressure and heart rate transiently. Pre-existing uncontrolled hypertension is a contraindication
• Psychological distress: Rarely, patients may experience dysphoric dissociative states. Proper preparation and therapist presence mitigate this risk
• Abuse potential: Ketamine has abuse potential and is a Schedule III controlled substance. Proper screening and supervised administration are essential
• Bladder toxicity: A concern with chronic recreational use at high doses, not typically seen with clinical dosing protocols

Legal and Regulatory Status

The regulatory landscape for ketamine-assisted treatments is nuanced:

• Ketamine (racemic): FDA-approved as an anesthetic. Its use for depression is off-label but legal when prescribed by a licensed physician. KAP using racemic ketamine operates under standard off-label prescribing authority
• Esketamine (Spravato): FDA-approved specifically for treatment-resistant depression and major depressive disorder with suicidal ideation. Must be administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program
• State regulations: Some states have additional requirements for ketamine prescribing and administration. Practitioners must be familiar with their state's specific regulations

Unlike psilocybin or MDMA, ketamine does not require DEA Schedule I research authorization, which has allowed the clinical field to develop more rapidly. However, the lack of specific FDA approval for KAP as a combined treatment means insurance coverage remains limited.

Cost Considerations

Transparency about cost is important because access barriers are real:

• Initial evaluation: $300-$500
• Individual ketamine dosing sessions: $400-$800 each
• Preparation and integration therapy sessions: $150-$300 each
• Full KAP course (6 dosing sessions + therapy): $3,000-$8,000 total
• Insurance coverage: Most plans do not cover off-label ketamine for depression. Spravato (esketamine) may be covered with prior authorization

These costs put KAP out of reach for many patients who could benefit from it. This is a systemic problem, not a clinical one, and advocates continue to push for broader insurance coverage as the evidence base grows.

The Future of Psychedelic-Assisted Therapy

KAP exists within a broader renaissance in psychedelic-assisted treatments. The field is moving rapidly:

• MDMA-assisted psychotherapy for PTSD: Phase 3 trials showed approximately 71% of participants no longer met PTSD criteria after treatment. FDA review is ongoing
• Psilocybin-assisted therapy for depression: Multiple Phase 2 trials have demonstrated significant efficacy. Phase 3 trials are underway
• Ketamine remains the most accessible: As a legal, already-approved medication, it can be prescribed now without waiting for the regulatory process to unfold for other psychedelics

The common thread across these approaches is the integration model: the drug opens a window of psychological and neurological flexibility, and structured psychotherapy takes advantage of that window to produce lasting change. Ketamine was the first to demonstrate this principle clinically, and its relative accessibility makes it the current standard-bearer for the psychedelic-assisted therapy paradigm.

As a field, we need to do this carefully. The enthusiasm around psychedelic medicine is warranted by the data, but it must be tempered by rigorous safety protocols, proper training, and honest communication about what these treatments can and cannot accomplish. Ketamine is not a cure for depression. It is a tool -- a powerful one -- that, when combined with skilled psychotherapy and comprehensive psychiatric care, can help people who have run out of other options.

Frequently Asked Questions

What is ketamine-assisted psychotherapy (KAP)?

KAP combines sub-anesthetic doses of ketamine with structured psychotherapy sessions. Unlike standalone ketamine infusions focused solely on symptom relief, KAP uses the neuroplasticity window following ketamine administration to deepen therapeutic work, including preparation sessions before and integration sessions after each ketamine dose.

How does KAP differ from ketamine infusions?

Standalone ketamine infusions deliver the drug without psychotherapy, relying on ketamine's pharmacological effects alone. KAP integrates psychotherapy before, during, and after ketamine sessions, using the neuroplasticity window to facilitate deeper psychological processing and more durable treatment gains.

What conditions does ketamine-assisted psychotherapy treat?

KAP is primarily used for treatment-resistant depression -- depression that has not responded to two or more adequate medication trials. It is also being studied for PTSD, severe anxiety, suicidal ideation, and obsessive-compulsive disorder. Patients must be carefully screened for contraindications including uncontrolled hypertension, active psychosis, and substance use disorders.

What does a typical KAP treatment course look like?

A typical course includes an initial psychiatric evaluation, 1-2 preparation sessions to establish therapeutic goals, 4-6 ketamine dosing sessions (usually spaced 1-2 weeks apart), and integration sessions after each dose to process the experience. The entire course spans approximately 8-12 weeks.

Is ketamine-assisted psychotherapy safe?

When administered by trained clinicians in a controlled medical setting, KAP has a favorable safety profile. Common side effects include transient dissociation, nausea, dizziness, and elevated blood pressure during the session. Serious adverse events are rare. Proper screening, medical monitoring during sessions, and post-session observation are essential safety measures.

Does insurance cover ketamine-assisted psychotherapy?

Most insurance plans do not cover KAP or ketamine infusions for psychiatric indications, as ketamine is used off-label for depression. The FDA-approved nasal spray esketamine (Spravato) may be covered by some insurance plans. Out-of-pocket costs for a full KAP course typically range from $3,000 to $8,000 depending on the number of sessions and provider.

Further Reading

• Ketamine Therapy for Depression
• Dr. Sultan's Approach to Depression Treatment
• Research Collaborators
• Publications